CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 14 enrolled
Drug / intervention
Cannabis +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03274440
NCT03274440Phase 2Completed
CompareCT.gov

Effects of Marijuana on Symptoms of Obsessive-Compulsive Disorder

New York State Psychiatric Institute·interventional·Posted Sep 7, 2017·Updated Nov 18, 2020

In Brief

A Phase 2 clinical trial evaluating Cannabis and Placebo for Obsessive-Compulsive Disorder. Completed, enrolled 14 participants across 1 site.

Detailed Summary

The purpose of this pilot research study is to test whether certain components of the marijuana plant, known as "cannabinoids", may help to reduce symptoms in patients with OCD. Specifically, patients enrolled in the study will smoke marijuana containing different concentrations of 2 different cannabinoids, THC and CBD. Both of these agents act on the brain's "endocannabinoid system," which has been hypothesized to play a role in OCD. Neither compound is currently FDA-approved for treating OCD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObsessive-Compulsive Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 7, 2017
Enrollment StartOct 1, 2017
Primary CompletionMar 1, 2019
Study CompletionOct 29, 2020
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 8.8 years ago

Interventions

Cannabisdrug

THC and CBD are "cannabinoids" which are found naturally in the marijuana plant. Both act on the brain's "endocannabinoid system," which has been hypothesized to play a role in OCD.

Placeboother

Placebo control group, not receiving THC or CBD.